The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of combination therapy with metronomic capecitabine (C) and fulvestrant (F) in the treatment of hormone receptor-positive metastatic breast cancer (HR+ MBC).
L. J. Blakely
No relevant relationships to disclose
L. S. Schwartzberg
No relevant relationships to disclose
G. Wang
No relevant relationships to disclose
B. G. Somer
No relevant relationships to disclose
B. M. Wheeler
No relevant relationships to disclose
E. J. Stepanski
No relevant relationships to disclose
M. Walker
No relevant relationships to disclose
A. Johns
No relevant relationships to disclose